Jefferies Group Comments on Gemphire Therapeutics Inc’s Q1 2017 Earnings (GEMP)
Gemphire Therapeutics Inc (NASDAQ:GEMP) – Jefferies Group issued their Q1 2017 EPS estimates for Gemphire Therapeutics in a report released on Thursday. Jefferies Group analyst M. Andrews anticipates that the brokerage will post earnings per share of ($0.84) for the quarter. Jefferies Group currently has a “Buy” rating and a $17.00 price target on the stock. Jefferies Group also issued estimates for Gemphire Therapeutics’ Q2 2017 earnings at ($0.79) EPS, Q3 2017 earnings at ($0.66) EPS, Q4 2017 earnings at ($0.55) EPS and FY2021 earnings at ($1.46) EPS.
Several other research analysts also recently weighed in on GEMP. Canaccord Genuity set a $17.00 target price on Gemphire Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 16th. Zacks Investment Research upgraded Gemphire Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, December 5th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.75.
Your IP Address:
Shares of Gemphire Therapeutics (NASDAQ:GEMP) opened at 10.1243 on Monday. The company’s 50 day moving average price is $9.86 and its 200 day moving average price is $9.94. The stock’s market capitalization is $93.85 million. Gemphire Therapeutics has a 12 month low of $7.25 and a 12 month high of $13.98.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Wednesday, March 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.24.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Clay Capital Management LLC bought a new position in shares of Gemphire Therapeutics during the third quarter valued at $131,000. Monashee Investment Management LLC acquired a new stake in Gemphire Therapeutics during the third quarter valued at approximately $144,000. Spark Investment Management LLC acquired a new stake in Gemphire Therapeutics during the third quarter valued at approximately $198,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Gemphire Therapeutics during the third quarter valued at approximately $3,976,000. Institutional investors own 14.85% of the company’s stock.
In related news, Director Andy Sassine bought 21,119 shares of the stock in a transaction on Friday, March 10th. The shares were bought at an average cost of $9.47 per share, for a total transaction of $199,996.93. Following the purchase, the director now owns 136,264 shares of the company’s stock, valued at approximately $1,290,420.08. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.